[ad_1]
KUALA LUMPUR: Kanger International Bhd (Kanger) said it has received support from the Malaysian Ministry of Science, Technology and Innovation (MOSTI) to purchase Covid-19 vaccines for use by the private sector in Malaysia.
In a statement today, the company said that the National Institutes of Biotechnology of Malaysia (NIBM), an agency under MOSTI, has no objection to the company contacting China National Pharmaceutical Group Corporation (Sinopharm) in purchasing the vaccines. .
“As countries around the world work to ensure the supply of the Covid-19 vaccine, it is necessary for both the public and private sectors to join forces.
“Recently, the governments of Malaysia and China signed an agreement to foster greater collaboration in the fight against the Covid-19 pandemic, including cooperation in research and development (R&D) and the supply of vaccines,” he said. Kanger CEO Steven Kuah Choon Ching.
He said the company is pleased to receive the support from MOSTI and NIBM as it demonstrates the government’s commitment to exploring all avenues to ensure Malaysians gain access to vaccines.
On September 29, Kanger announced that it aims to venture into the distribution of Covid-19 vaccines and had signed a collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd, a subsidiary of Sinopharm, for the distribution of the vaccines.
Sinopharm, a Chinese state-owned company, is the oldest and largest biotechnology company in China.
It has developed two Covid-19 vaccines that have already entered phase three trials, which is the final stage before being approved for general use in more than 10 countries. -Called
[ad_2]
